Harvard Bioscience raises FY2026 revenue growth outlook to 3%-5%
HBIO•FY2026 outlook raised
Harvard Bioscience raised full-year 2026 revenue guidance to 3%-5% year-over-year growth.
- Adjusted gross margin is expected at 57%-59%, reflecting a higher volume of lower-margin CMT products, plus geographic mix.
- Adjusted EBITDA growth is forecast at 6%-10%; the target was maintained as sales momentum offsets mix-related margin pressure.
- Third-quarter revenue outlook was set at $21 million-$22.6 million; adjusted EBITDA is seen at $1.5 million-$2.5 million.
- Guidance follows second-quarter revenue of $22.7 million, up 11% year over year; adjusted EBITDA rose to $1.7 million.
